The FDA this week sent 30 telehealth companies warning letters about their "illegal" sales of compounded GLP-1s, building off increasing pressure to tamp down on the sale of these unapproved medications. According to the FDA, the companies they contacted made "false or misleading claims" about the GLP-1 products they sold on their websites, including implying "sameness with FDA-approved products and obscuring product sourcing." With the current state of GLP-1 availability, compounded versions of drugs like tirzepatide and semaglutide are meant to be personalized for patient-specific prescriptions. When branded drugs are not in shortage, compounding pharmacies are not permitted to mass market compounded versions of the medication. Due to the ostensibly hyper-specific nature of compounded drugs, they are not FDA-approved drugs, though compounding pharmacies are regulated by both state and federal agencies to some degree.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
